Product nameAnti-CD45RO antibody [UCHL1], prediluted
See all CD45RO primary antibodies
DescriptionMouse monoclonal [UCHL1] to CD45RO, prediluted
SpecificityThis antibody reacts with a 180 kD glycoprotein of the CD45 family, which is present on most thymocytes and activated T cells, but only on a proportion of resting T cells. It reacts with most thymocytes, a subpopulation of resting cells within both the CD4 and CD8 subsets, and mature activated T cells.
Tested applicationsSuitable for: IHC-P, IHC-Frmore details
Species reactivityReacts with: Human
BALB/C mice were immunized with the IL-2 dependent T cell line CA1.
Storage instructionsShipped at 4°C. Store at +4°C. Do Not Freeze.
Storage bufferPreservative: 0.05% Sodium azide
Concentration information loading...
Light chain typekappa
- Anti-CD45RO antibody [UCHL1] (FITC) (ab210385)
- Anti-CD45RO antibody [UCHL1] (PerCP/Cy5.5®) (ab210386)
- Anti-CD45RO antibody [UCHL1] (Allophycocyanin/Cy7 ®) (ab218632)
- Anti-CD45RO antibody [UCHL1] (redFluor™ 710) (ab242256)
- Anti-CD45RO antibody [UCHL1] (Phycoerythrin) (ab77217)
- Anti-CD45RO antibody [UCHL1] (PE/Cy5®) (ab95520)
- Anti-CD45RO antibody [UCHL1] (Allophycocyanin) (ab95521)
Our Abpromise guarantee covers the use of ab916 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
No further titration is required.
We suggest an incubation period of 30-60 minutes at room temperature.
However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user.
Overfixation in formalin should be avoided.
Enzymatic predigestion can cause false positive staining of non T cell tumors.
FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity.
Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
- B220 antibody
- CD45 antibody
- cd45 antigen antibody